3rd Quarter - Report
THE UNITED STATES PHARMACOPEIAL CONVENTION for THE UNITED STATES PHARMACOPEIAL CONVENTION
Income
—
Expenses
$90,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 4521 - America COMPETES Act: Provisions related to advanced pharmaceutical manufacturing and pharmaceutical supply chain resiliency. Fiscal Year 2023 Consolidated Appropriations Act; H.R. 7667 - Food and Drug Amendments of 2022: Provisions related to the Prescription Drug User Fee Reauthorization and FDA funding. S. 4090 - Dietary Supplement Listing Act of 2022: Provisions related to mandatory product listing for dietary supplements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH M. HILL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.